Next Article in Journal
Dyspnoea and Impaired Ventricular Filling Due to Infiltration of the Left Atrium with a Lung Adenocarcinoma
Previous Article in Journal
Bureaucracy and Medicine, an Unholy Marriage
 
 
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Triple Percutaneous Patent Foramen Ovale Closure

Cardiology, Bern University Hospital, CH-3010 Bern, Switzerland
*
Author to whom correspondence should be addressed.
Cardiovasc. Med. 2012, 15(9), 253; https://doi.org/10.4414/cvm.2012.01692
Submission received: 26 June 2012 / Revised: 26 July 2012 / Accepted: 26 August 2012 / Published: 26 September 2012

Abstract

Percutaneous patent foramen ovale (PFO) closure is mainly performed for secondary prevention of presumed paradoxical embolism. Since a residual shunt has been associated with recurrent events, complete PFO closure is desirable. We report the first case of ultimately successful percutaneous PFO closure using successively 3 Amplatzer PFO devices.

Introduction

Secondary prevention of presumed paradoxical embolism constitutes the main indication for percutaneous closure of the patent foramen ovale (PFO) [1,2,3,4]. A residual shunt has been associated with recurrent events [5]. Complete occlusion was reported in 51 to 100% of patients [5,6,7], depending on device type and on the methodology used for assessment of a residual shunt. It was >90% with a single Amplatzer PFO Occluder (APFO, St. Jude Medical Corporation, Plymouth, Minnesota) [6].
We report a case of percutaneous closure of a large PFO associated with an atrial septal aneurysm for secondary stroke prevention using successively 3 Amplatzer PFO Occluder devices.

Case report

A 40-year-old previously healthy male farmer, known for dyslipidaemia (total cholesterol 8.1 mmol/l; LDL 5.6 mmol/l; HDL 1.67 mmol/l) and former smoker (10 pack-years) suffered a minor stroke with transient hemiparesis of the right arm and transient motor aphasia. The patient reported no other similar symptoms in the past and had no current medication. Brain magnetic resonance imaging demonstrated a recent lesion of the left insular cortex as well as several other older bilateral ischaemic sequelae suggesting previous asymptomatic events possibly related to the PFO. Holter- ECG, computed tomography including contrast-enhanced angiography of the intra- and extracerebral vessels, as well as screening for thrombophilia were normal. Contrast transoesophageal echocardiography (TOE) revealed the presence of a PFO grade III [2] (>20 bubbles of aerated colloid solution crossing the interatrial septum after a sustained Valsalva manoeuvre) with spontaneous right-to-left shunt and a large atrial septal aneurysm. The patient was referred for percutaneous PFO closure. The intervention was performed under local anaesthesia without intraprocedural echocardiographic guidance or balloon sizing [7]. A 9 French sheath was placed in the right femoral vein and the PFO was crossed under fluoroscopic guidance in the anteroposterior view. After a first attempt with an obviously undersized 25-mm, a 30-mm APFO was correctly implanted (Figure 1). A contrast transthoracic echocardiogram (TTE) performed the next day confirmed a stable device position and failed to detect any residual shunt. The patient was discharged and instructed to continue clopidogrel 75 mg for 1 month and acetylsalicylic acid 100 mg for 5 months.
Six months later, follow-up contrast TOE documented a residual shunt grade III (Figure 2). Using the same technique, a second 25-mm APFO was implanted (Figure 3). Contrast TTE performed the next day did not detect any residual shunt. Clopidogrel 75 mg was again prescribed for 1 month and acetylsalicylic acid 100 mg for 5 months.
Six months after implantation of the second device, contrast TOE revealed correct position of both devices but a persisting shunt grade II (Figure 4). A third APFO (18-mm) was implanted using the same technique (Figure 5). Contrast TTE at discharge the same day assessed good position of the device without any residual shunt. Clopidogrel 75 mg was again prescribed for 1 month and acetylsalicylic acid 100 mg for 5 months. Six months after implantation of the third device, contrast TOE finally showed complete occlusion (Figure 6) and both platelet inhibitors were stopped.
The patient has been regularly followed during 3 years and remained asymptomatic. There were no complications related to the 3 interventions nor any recurrent ischaemic events.

Discussion

To our knowledge this is the first report of successful percutaneous PFO closure using successively 3 APFO devices.
Several nonrandomised long-term data suggest superiority of transcatheter PFO closure over medical treatment [8,9,10,11]. However, the recently published randomised CLOSURE I trial failed to confirm the benefits of device closure [12]. This fact may be related to the short follow-up (2 years) and to the use of a suboptimal device (STARFlex occluder) prone to incomplete closure and thrombus formation. It is of note that residual shunt has been identified as a predicting cause of recurrence [5]. Using the Amplatzer technique, implantation of a second device is required in about 3% of the cases, and complete PFO closure can be expected in 80% of these patients [5,6]. Hence, the question of a third device arises in about 0.6% of all cases. The subjective component of a patient wanting the hole that menaces his brain completely closed represents an asset in the indication for repeat PFO closure.

Funding/potential competing interests

B. Meier: research grant and speaker bureau for St. Jude Medical.

References

  1. Lechat, P.; Mas, J.L.; Lascault, G.; Loron, P.; Theard, M.; Klimczac, M.; et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318, 1148–1152. [Google Scholar] [CrossRef] [PubMed]
  2. Webster, M.W.; Chancellor, A.M.; Smith, H.J.; Swift, D.L.; Sharpe, D.N.; Bass, N.M.; et al. Patent foramen ovale in young stroke patients. Lancet 1988, 2, 11–12. [Google Scholar] [CrossRef] [PubMed]
  3. Mas, J.L.; Arquizan, C.; Lamy, C.; Zuber, M.; Cabanes, L.; Derumeaux, G.; et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345, 1740–1746. [Google Scholar] [CrossRef] [PubMed]
  4. Handke, M.; Harloff, A.; Olschewski, M.; Hetzel, A.; Geibel, A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007, 357, 2262–2268. [Google Scholar] [CrossRef] [PubMed]
  5. Wahl, A.; Kunz, M.; Moschovitis, A.; Nageh, T.; Schwerzmann, M.; Seiler, C.; et al. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart 2008, 94, 336–341. [Google Scholar] [CrossRef] [PubMed]
  6. Wahl, A.; Praz, F.; Stinimann, J.; Windecker, S.; Seiler, C.; Nedeltchev, K.; et al. Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. Swiss Med Wkly 2008, 138, 567–572. [Google Scholar] [PubMed]
  7. Wahl, A.; Meier, B. Patent foramen ovale and ventricular septal defect closure. Heart 2009, 95, 70–82. [Google Scholar] [CrossRef] [PubMed]
  8. Windecker, S.; Meier, B. Percutaneous patent foramen ovale (PFO) closure: It can be done but should it? [editorial; comment]. Catheter Cardiovasc Interv 1999, 47, 377–380. [Google Scholar] [PubMed]
  9. Wohrle, J. Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006, 368, 350–352. [Google Scholar] [CrossRef] [PubMed]
  10. Khairy, P.; O’Donnell, C.P.; Landzberg, M.J. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003, 139, 753–760. [Google Scholar] [CrossRef] [PubMed]
  11. Wahl, A.; Juni, P.; Mono, M.L.; Kalesan, B.; Praz, F.; Geister, L.; et al. Long- term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation 2012, 125, 803–812. [Google Scholar] [CrossRef] [PubMed]
  12. Furlan, A.J.; Reisman, M.; Massaro, J.; Mauri, L.; Adams, H.; Albers, G.W.; et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012, 366, 991–999. [Google Scholar] [CrossRef] [PubMed]
Figure 1. (A) Undersized 25-mm Amplatzer PFO Occluder. (B) 30-mm Amplatzer PFO Occluder before release. (C) After release. Angiography through the sidearm of the delivery sheath delineates the septum secundum (SS) which has to be sandwiched between the cranial disk parts (Pacman sign). LA = left atrium; RA = right atrium.
Figure 1. (A) Undersized 25-mm Amplatzer PFO Occluder. (B) 30-mm Amplatzer PFO Occluder before release. (C) After release. Angiography through the sidearm of the delivery sheath delineates the septum secundum (SS) which has to be sandwiched between the cranial disk parts (Pacman sign). LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g001
Figure 2. Contrast TEE 6 months after implantation with residual shunt grade III. APFO = 30-mm Amplatzer PFO Occluder; LA = left atrium; RA = right atrium.
Figure 2. Contrast TEE 6 months after implantation with residual shunt grade III. APFO = 30-mm Amplatzer PFO Occluder; LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g002
Figure 3. Placement of a second 25-mm Amplatzer PFO Occluder (arrows), with the right disk sandwiched like a banana by the initial. 30-mm Amplatzer PFO Occluder. LA = left atrium; RA = right atrium.
Figure 3. Placement of a second 25-mm Amplatzer PFO Occluder (arrows), with the right disk sandwiched like a banana by the initial. 30-mm Amplatzer PFO Occluder. LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g003
Figure 4. Contrast TEE 6 months after implantation of the second device with residual shunt grade 2 (arrow). LA = left atrium; RA = right atrium.
Figure 4. Contrast TEE 6 months after implantation of the second device with residual shunt grade 2 (arrow). LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g004
Figure 5. (A) Third intervention Residual PFO passed with a 0.014 inch Magnum coronary guidewire. (B) Deployment of an 18-mm Amplatzer PFO Occluder. (C) Final angiographic result with 3 Amplatzer PFO Occluder in place. LA = left atrium; RA = right atrium.
Figure 5. (A) Third intervention Residual PFO passed with a 0.014 inch Magnum coronary guidewire. (B) Deployment of an 18-mm Amplatzer PFO Occluder. (C) Final angiographic result with 3 Amplatzer PFO Occluder in place. LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g005
Figure 6. Final contrast TEE showing complete occlusion 6 months after the third intervention. APFO = left disks of first (left) and third (right) PFO Occluders; LA = left atrium; RA = right atrium.
Figure 6. Final contrast TEE showing complete occlusion 6 months after the third intervention. APFO = left disks of first (left) and third (right) PFO Occluders; LA = left atrium; RA = right atrium.
Cardiovascmed 15 00253 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Praz, F.; Wahl, A.; Meier, B. Triple Percutaneous Patent Foramen Ovale Closure. Cardiovasc. Med. 2012, 15, 253. https://doi.org/10.4414/cvm.2012.01692

AMA Style

Praz F, Wahl A, Meier B. Triple Percutaneous Patent Foramen Ovale Closure. Cardiovascular Medicine. 2012; 15(9):253. https://doi.org/10.4414/cvm.2012.01692

Chicago/Turabian Style

Praz, Fabien, Andreas Wahl, and Bernhard Meier. 2012. "Triple Percutaneous Patent Foramen Ovale Closure" Cardiovascular Medicine 15, no. 9: 253. https://doi.org/10.4414/cvm.2012.01692

APA Style

Praz, F., Wahl, A., & Meier, B. (2012). Triple Percutaneous Patent Foramen Ovale Closure. Cardiovascular Medicine, 15(9), 253. https://doi.org/10.4414/cvm.2012.01692

Article Metrics

Back to TopTop